Molecular Determinants of Sotorasib Efficacy in Patients with Advanced KRASG12C-mutated NSCLC By Ogkologos - June 6, 2025 527 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from integrated analyses of sotorasib clinical efficacy biomarkers in the CodeBreaK 100 and CodeBreaK 200 studies Source RELATED ARTICLESMORE FROM AUTHOR Patient Guide in Testicular Cancer Now Available Also in Italian Adding 177Lu-PNT2002 to SBRT Significantly Improves PFS in Patients with Oligorecurrent Hormone-Sensitive Prostate Cancer A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer MOST POPULAR Strong Independent Association of TILs with OS for Patients with ERBB2-positive... February 26, 2025 Sex, intimacy and cancer – That Cancer Conversation April 28, 2023 T-DM1 is Active and Well Tolerated in Patients with HER2-positive Metastatic... July 9, 2020 Better together: improving brain tumour treatment February 13, 2023 Load more HOT NEWS Unusual or Nonreportable Results from Prenatal cfDNA-Sequencing Suggestive for an Occult... What Cancer Caregivers Should Know About Hospice Care at Home: A... Tepotinib Shows Activity in Advanced NSCLC with a MET Exon 14... Potential of NOTCH1 Mutation to Predict Anti-PD1 Treatment Outcomes in Patients...
